SGNTUC-016: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic Her2+ breast cancer

This Study is
No Longer Enrolling

Details
Age

Adult

Type of Study

Treatment

Scope

National

Locations

Greeley Campus
Harmony Campus
Medical Center of the Rockies
Poudre Valley Hospital

Study ID

Protocol Number: 19-6076

More information available at ClinicalTrials.gov: NCT03975647

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers